Alzheimer’s ‘breakthrough’ stalls: why a much-hyped drug is facing approval delays
by Melissa Davey Medical editor from Science | The Guardian on (#6KJMP)
The benefits of drugs such as donanemab, aducanumab and lecanemab are proving harder to quantify than potential harms, experts say
It was heralded in news articles as a breakthrough", a turning point" and a gamechanger" for Alzheimer's disease. Some experts went so far as to call the drug, donanemab, the beginning of the end" for the debilitating condition.
Pharmaceutical company Eli Lilly in May 2023 released data from a clinical trial they said showed donanemab slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease by 35% over 18 months.
Continue reading...